Novartis India Limited
NOVARTIND (NSE)

674.30

1,664.90
Proj. ROE (%)
-
Proj. P/E (x)
-
Proj EV / EBITDA (x)
-
Proj. P/BV (x)
-
Proj. Revenue ( Cr.)
-

Stock View

-
Share on
The average score for Novartis India Limited stands at 8 against 3, three months back.

Novartis India Limited is an India-based company, which is primarily engaged in the business of trading of drugs and pharmaceuticals. The Company focuses on over three divisions, including pharmaceuticals, eye care and generic medicines. In India, its pharmaceutical business is focused on bone and pain, calcium portfolio, gynecology and neurosciences, and the generics business is focused on gynecology, anti-tuberculosis (TB) and anti-infectives. It focuses on therapeutic areas, such as cardiovascular, renal and metabolism, immunology and dermatology, ophthalmology, neuroscience and respiratory. It develops gene therapies for patients and families devastated by rare and life-threatening neurological genetic diseases. It is developing a chimeric antigen receptor (CAR)-T platform for various investigational CAR-T therapies in its pipeline. The Company has presence in various locations in India, including Delhi, Bengaluru, Kolkata, Chennai and Lucknow.

Disclaimer : All estimates (1 year forward) are based on Consensus View provided by Refinitiv.

Technical Data
50 DMA()
604.93
100 DMA ()
624.06
200 DMA ()
705.06
52 Weeks Range
565.30
1,098.00
Street View :-
Bearish
Open ZERO Brokerage Demat Account
Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity